An open-label extension study to evaluate safety and efficacy of Pazopanib in patients with advanced renal cell carcinoma.
Sternberg, C Davis, I Deen, K Sigal, E Hawkins, Robert E
Sternberg, C
Davis, I
Deen, K
Sigal, E
Hawkins, Robert E
Citations
Altmetric:
Abstract
Evaluation of the safety and efficacy of pazopanib, a multikinase angiogenesis inhibitor, in a single-arm, open-label, extension study (VEG107769/NCT00387764) for placebo-treated patients with advanced renal cell carcinoma (RCC) from a randomized, double-blind, placebo-controlled phase III study (VEG105192/NCT00334282).
Description
Date
2014
Publisher
Collections
Keywords
Type
Article
Citation
An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma. 2014, 87 (6):342-50 Oncology